International Aids Vaccine Initiative

Rwanda faces a Marburg disease outbreak with 49 infected and 12 deaths. WHO assesses risk as very high, with potential spread to neighboring countries. No licensed vaccines or treatments exist, but human trials for experimental vaccines and therapeutics are imminent. 28 vaccine candidates are in development, with four prioritized by WHO. The Sabin Vaccine Institute's adenovirus-based vaccine is most advanced, with 700 doses shipped to Rwanda. WHO also organizes the SOLIDARITY PARTNERS trial to evaluate treatments like remdesivir and MBP091. Rwanda's Ministry of Health urges public vigilance and hygiene.

Experimental Marburg vaccines and therapeutics, including Gilead's remdesivir and Mapp's MBP-091, will soon arrive in Rwanda for clinical trials. Rwanda, facing its first Marburg outbreak with 41 cases, aims to start trials within days to protect healthcare workers. The Sabin Vaccine Institute is sending 700 doses of a single-dose vaccine, believed to be the furthest along in development.